

10/501295
DT04 Rec'd PCT/PTO 12 JUL 2004

Appendix A

Claim Amendments

1. (Currently amended) Inclusion complex formed of element A and element B, wherein element A is chosen from pantoprazole, a solvate of pantoprazole, a hydrate of pantoprazole, a salt of pantoprazole with a base, a solvate of a salt of pantoprazole with a base, a hydrate of a salt of pantoprazole with a base, an enantiomer of pantoprazole, a solvate of an enantiomer of pantoprazole, a hydrate of an enantiomer of pantoprazole, [[or]] a salt of an enantiomer of pantoprazole, a solvate of a salt of an enantiomer of pantoprazole, a hydrate of a salt of an enantiomer of pantoprazole, or a mixture thereof; and wherein element B is chosen from cyclodextrin, a hydrate of cyclodextrin, a derivative of cyclodextrin or a mixture thereof.
2. (Currently amended) Inclusion complex according to claim 1 ~~formed of~~ wherein element A is chosen from pantoprazole sodium sesquihydrate (= pantoprazole sodium x 1.5 H₂O), (-)-pantoprazole sodium

sequihydrate, ~~[[or]]~~ pantoprazole magnesium dihydrate
or a mixture thereof.

3. (Currently amended) Inclusion complex according to claim 1 ~~or 2~~, wherein element B ~~the cyclodextrin~~ is β -cyclodextrin.
4. (Currently amended) Method of preparing ~~preparation of~~ an inclusion complex according to claim 1 comprising ~~any of claims 1 to 3~~ by reacting element A with element B ~~pantoprazole with the cyclodextrin~~ in a suitable solvent.
5. (Currently amended) Method according to claim 4, wherein the solvent is ~~essentially~~ ethanol.
6. (Currently amended) Inclusion complex prepared by the method ~~obtainable~~ according to claim 4.
7. (Currently amended) Inclusion complex according to claim 1, which is a 1/1 ~~(pantoprazole/cyclodextrin)~~ inclusion complex.
8. (Currently amended) Administration form comprising an

inclusion complex according to claim 1 ~~any of claims 1~~
~~to 3~~ together with a suitable pharmaceutical
~~auxiliaries~~ auxiliary.

9. (Canceled)

10. (Currently amended) Method of treating or preventing
a condition treatable or preventable with a pyridine-
2ylmethylsulfinyl-1H-benzimidazole, which comprises
administering to a subject prone to or afflicted with
a condition a pharmaceutically acceptable
administration form according to claim 8 comprising
[[an]] therapeutically effective amount of the
~~pantoprazole~~ inclusion complex.

11. (New) Inclusion complex according to claim 2 wherein
element B is β -cyclodextrin.

12. (New) Method of preparing an inclusion complex
according to claim 1 comprising reacting element A
with element B in a suitable solvent.

13. (New) Method of preparing an inclusion complex
according to claim 3 comprising ~~by~~ reacting element A

with element B in a suitable solvent.

14.(New) Administration form comprising an inclusion complex according to claim 2 together with a suitable pharmaceutical auxiliary.

15.(New) Administration form comprising an inclusion complex according to claim 3 together with a suitable pharmaceutical auxiliary.